NCT03137368 - A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP） | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

August 9, 2018

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2023

Conditions

CYP2D6 Polymorphism

Interventions

DRUG

Exemestane Tablets

drug therapy

OTHER

ovarian function suppression/ablation

Gonadotropin-releasing hormone analogue Goserelin Injection 3.6mg or Leuprorelin Injection 3.75 mg, a subcutaneous injection should be done every 28±2 days; or Bilateral ovariectomy.

GENETIC

CYP2D6*10 gene test

CYP2D6\*10 gene test

DRUG

Tamoxifen

drug therapy

Trial Locations (1)

100010

CancerIHCAMS, Beijing